Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Oral Pirfenidone for the Pulmonary Fibrosis of Hermansky-Pudlak Syndrome
This study is currently recruiting participants.
Study NCT00001596 Information provided by National Institutes of Health Clinical Center (CC)
First Received: November 3, 1999 Last Updated: August 24, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Albinism
Inborn Errors of Metabolism
Oculocutaneous Albinism
Platelet Storage Pool Deficiency
Pulmonary Fibrosis
Additional conditions recognized in this trial
Albinism, Oculocutaneous
Fibrosis
Hermanski-Pudlak Syndrome
Metabolism, Inborn Errors
Syndrome
More general conditions related to this trial
Amino Acid Metabolism, Inborn Errors
Blood Coagulation Disorders
Blood Coagulation Disorders, Inherited
Blood Platelet Disorders
Disease
Eye Diseases
Eye Diseases, Hereditary
Genetic Diseases, Inborn
Hematologic Diseases
Hemorrhagic Disorders
Hypopigmentation
Lung Diseases
Lung Diseases, Interstitial
Metabolic Diseases
Pathologic Processes
Pigmentation Disorders
Respiratory Tract Diseases
Skin Diseases
Skin Diseases, Genetic
Interventions listed in this trial
Pirfenidone (Deskar)
Pirfenidone
More general drug interventions related to this trial
Analgesics
Analgesics, Non-Narcotic
Anti-Inflammatory Agents
Anti-Inflammatory Agents, Non-Steroidal
Antineoplastic Agents
Antirheumatic Agents
Central Nervous System Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses
Sponsors listed in this trial
National Human Genome Research Institute (NHGRI)
Back to top of Main Content
